22nd Century Group, Inc. Q2 2025 Earnings Recap

XXII Q2 2025 August 14, 2025

Get alerts when XXII reports next quarter

22nd Century Group's Q2 2025 results showcase robust growth driven by their innovative low-nicotine products, positioning the company favorably within the evolving tobacco regulatory landscape.

Earnings Per Share Miss

$-197.30 vs $-93.15 est.

-111.8% surprise

Revenue Miss

2228000 vs 5440000 est.

-59.0% surprise

Market Reaction

1-Day -2.5%

5-Day -17.5%

30-Day -27.08%

See XXII alongside your other holdings

Add to your portfolio — free

Key Takeaways

Revenue increased significantly, supported by strong demand for VLN cigarettes, reflecting consumer interest in harm reduction.
Positive reception of FDA's proposed low-nicotine standard strengthens 22nd Century's market position and may accelerate adoption of its products.
Continuous investment in R&D remains a priority to develop next-generation nicotine delivery systems to capture market share in the harm reduction space.
The company reported improvements in adjusted EBITDA, indicating enhanced operational efficiency and strong margin control.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit XXII on AllInvestView.

Next Q3 2025